Related Experiment Videos

Signalling mechanisms in PAF-induced intestinal failure

Ingmar Lautenschläger1, Yuk Lung Wong2, Jürgen Sarau3

  • 1Department of Anaesthesiology and Intensive Care Medicine, University Medical Centre Schleswig-Holstein, Campus Kiel, Kiel, Germany. ingmar.lautenschlaeger@uksh.de.

Scientific Reports
|October 19, 2017
PubMed

Insights

Platelet-activating factor (PAF) causes capillary leakage and gut issues in intensive care. Targeting IP3 receptors or Rho-kinase shows therapeutic promise without negative side effects.

Area of Science:

  • Physiology
  • Pharmacology
  • Intensive Care Medicine

Background:

  • Capillary leakage syndrome, vasomotor disturbances, and gut atony are critical issues in intensive care.
  • Platelet-activating factor (PAF) is implicated in these conditions, but its signaling mechanisms remain unclear.
  • Understanding PAF's role is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the signaling pathways involved in PAF-induced intestinal dysfunction.
  • To analyze the roles of calcium, cAMP, myosin light chain kinase, and Rho-kinase in PAF's effects.
  • To evaluate potential therapeutic targets for PAF-mediated pathologies.

Main Methods:

  • Utilized an isolated perfused rat small intestine model.
  • Administered PAF and various inhibitors: calcium deprivation, 2-APB (IP-receptor antagonist), PDE inhibitors, AC activators, ML-7 (MLCK inhibitor), and Y27632 (ROCK inhibitor).
  • Assessed PAF-induced vasoconstriction, capillary/mucosal leakage, edema, malabsorption, and atony.

Main Results:

  • PAF-induced vasoconstriction and hyperpermeability involve IP3 receptors, extracellular calcium, and Rho-kinase.
  • cAMP-elevating treatments reduced hypertension and edema but worsened dysmotility and malabsorption.
  • 2-APB and Y27632 improved most PAF-induced malfunctions without adverse effects.

Conclusions:

  • PAF-induced intestinal vasoconstriction and hyperpermeability share common signaling pathways.
  • Rho-kinase and IP3 receptors are key mediators of PAF's detrimental effects.
  • Targeting Rho-kinase or IP3 receptors may offer therapeutic benefits for PAF-related conditions in intensive care.

Related Concept Videos